Journal
NATURE CHEMISTRY
Volume 5, Issue 1, Pages 54-60Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/NCHEM.1504
Keywords
-
Categories
Funding
- Boehringer Ingelheim
- DuPont
- Eli Lilly
- Amgen
- AstraZeneca
- Roche
- A. P. Sloan Foundation
- University of California, Los Angeles
- ACS Division of Organic Chemistry
- Foote Family
- Pfizer
- National Science Foundation [CHE-1048804]
- National Center for Research Resources [S10RR025631]
- NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR025631] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The pyridine heterocycle continues to play a vital role in the development of human medicines. More than 100 currently marketed drugs contain this privileged unit, which remains highly sought after synthetically. We report an efficient means to access di- and trisubstituted pyridines in an efficient and highly controlled manner using transient 3,4-pyridyne intermediates. Previous efforts to employ 3,4-pyridynes for the construction of substituted pyridines were hampered by a lack of regiocontrol or the inability to later manipulate an adjacent directing group. The strategy relies on the use of proximal halide or sulfamate substituents to perturb pyridyne distortion, which in turn governs regioselectivities in nucleophilic addition and cycloaddition reactions. After trapping of the pyridynes generated in situ, the neighbouring directing groups may be removed or exploited using versatile metal-catalysed cross-coupling reactions. This methodology now renders 3,4-pyridynes as useful synthetic building blocks for the creation of highly decorated derivatives of the medicinally privileged pyridine heterocycle.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available